Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ITOS
ITOS | US
9.10
USD-0.33
-3.50%
ITOS | US
About ITOS
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
9.10
Open
9.35
High
9.36
Low
8.91
Iteos Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448 an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains which is in Phase 1/2 clinical trial as well as used to engage the Fc gamma receptor or Fc"R to activate dendritic cells natural killer cells and macrophages and to promote antibody-dependent cellular cytotoxicity or ADCC activity. Iteos Therapeutics Inc. was founded in 2011 and is headquartered in Watertown Massachusetts."
View LessITOS | US
Risk
54.0
Sharpe
-0.16
Luna's Score
31/100
Recommendation
Sell
Luna says (ITOS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
61.1%1 month
54.0%3 months
75.9%6 months
88.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
12.56
Price to book
0.53
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.50
Ent. to rev.
1.26
PEG
-
Other Fundamentals
EBITDA
-139.26M
MarketCap
332.35M
MarketCap(USD)
332.35M
Div. yield
-
Op. margin
-37.92
Erngs. growth
-88.60
Rev. growth
-100.00
Ret. on equity
-16.80
Short ratio
5.07
Short perc.
24.70
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.48
Range1M
2.63
Range3M
9.39
Volumes: Market Activity
Rel. volume
1.47
Price X volume
8.85M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.50 | - | Par |
| Ent. to Revenue | 1.26 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 75.95 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 332.35M | - | Emerging |
